| Not Yet Recruiting | A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophage NCT07517211 | Jonsson Comprehensive Cancer Center | — |
| Not Yet Recruiting | Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III G NCT07439484 | Jonsson Comprehensive Cancer Center | N/A |
| Withdrawn | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers NCT05296005 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Enrolling By Invitation | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gas NCT07139951 | Mayo Clinic | Phase 2 |
| Recruiting | Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in P NCT06364410 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial NCT06203600 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Active Not Recruiting | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastr NCT05836584 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcin NCT06078709 | Mayo Clinic | Phase 2 |
| Recruiting | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000 | Northwestern University | Phase 2 |
| Recruiting | Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Loca NCT05651594 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastati NCT05677490 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adeno NCT05041153 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of NCT04929392 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advance NCT04391049 | NRG Oncology | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or NCT04535401 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Adv NCT04660760 | Academic and Community Cancer Research United | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Eso NCT04460937 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gast NCT03641313 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer NCT04522336 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Completed | Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esopha NCT04097028 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Recruiting | Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer NCT03801876 | NRG Oncology | Phase 3 |
| Suspended | Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Und NCT03604991 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Active Not Recruiting | Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal NCT03784326 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer NCT03776487 | M.D. Anderson Cancer Center | Phase 2 |